patient outcomes and systemic sclerosis Archives

Abstract Number: 790 • ACR/ARHP Annual Meeting 2018
Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet
Kelly Jensen¹, Linda Wang², Rosemary Kovacic², Veronika K. Jaeger³, Monika Lammi⁴ and Lesley Ann Saketkoo⁵, ¹Tulane University School of Medicine, New Orleans, LA, ²Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, ³Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁴GI Motility Program at Ochsner Medical Center, New Orleans, LA, ⁵Tulane, New Orleans, LA
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease affecting multiple organ systems including vascular, musculoskeletal, cardiac, renal, pulmonary, and gastrointestinal (GI). 90% of SSc…
Abstract Number: 1739 • ACR/ARHP Annual Meeting 2018
What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?
Jessica Zhu¹, Craig Gale², Joshua Biber³, Mandana Nikpour⁴, Murray Baron⁵ and Tracy M. Frech⁶, ¹School of Medicine, University of Utah, Salt Lake City, UT, ²Bioinformatics, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴The University of Melbourne, Melbourne, Australia, Melbourne, Australia, ⁵Department of Medicine, McGill University, Montreal, QC, Canada, ⁶Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: The implementation of patient reported outcome measures (PROMs) is increasingly recognized as a critical aspect of clinical practice. The use of gastrointestinal (GI) PROMs…
Abstract Number: 2687 • ACR/ARHP Annual Meeting 2018
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
Vivek Nagaraja¹, John Powers², Celia J. F. Lin³, Benjamin Brennan⁴, Veronica J. Berrocal⁵ and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Maryland School of Medicine, Rockville, MD, ³Genentech, Inc., South San Francisco, CA, ⁴School of Public Health, University of Michigan, Ann Arbor, MI, ⁵Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment benefit is demonstrated by evidence that interventions have positive impacts on how patients feel, function, and/or survive (FDA Guidance, 21CFR314.510). The ACR CRISS,…
Abstract Number: 2668 • ACR/ARHP Annual Meeting 2017
Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients
Yossra A Suliman¹, Suzanne Kafaja², Mohamed Alemam³, yasser Shaweesh⁴, Kasra Tavakoli⁵ and Daniel E. Furst⁶, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁴John H. Stroger Jr. Hospital of cook county, chicago, IL, ⁵Department of medicine, university of California Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Gastrointestinal tract (GIT) involvement in systemic sclerosis (SSc) is the most common internal organ involvement. Among the few validated patient-reported outcome measures for GI…
Abstract Number: 2694 • ACR/ARHP Annual Meeting 2017
Performance of Patient-Reported Outcomes Measurement Information Systems (PROMIS) Promis-29 and Promis Self-Efficacy in Systemic Sclerosis (SSc)
Janet L. Poole¹, Veronica J. Berrocal², Jennifer Serrano³, Erica Bush³ and Dinesh Khanna³, ¹Health Sciences Ctr OT Program, 1 University of New Mexico, Albuquerque, NM, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Patient reported outcomes are important to measure the effectiveness of non-pharmacological and pharmacological interventions. The goal of PROMIS is to develop standardized items banks…
Abstract Number: 2718 • ACR/ARHP Annual Meeting 2014
The UCLA Gastrointestinal Tract Questionnaire (GIT)2.0 and GI Visual Analogue Scale(GI-VAS) Reflect Different Aspects of GI Involvement in Systemic Sclerosis
Yossra Suliman^1,2, Yasser Shaweesh³, Suzanne Kafaja^4,5,6, Lewei Duan⁷ and Daniel E. Furst⁸, ¹Division of Rheumatology, Department of Medicine., David Geffen School of Medicine, University of California Los Angeles,, Los Angeles, CA, ²Rheumatology and Rehabilitation department, Faculty of Medicine, Assiut university, Assiut, Egypt, ³Division of Rheumatology, Department of Medicine., David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ⁴Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁵Medicine, University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁶David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁷David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁸University of California at Los Angeles, Los Angeles, CA
Background/Purpose UCLA GIT2.0 is a validated measure for assessing the severity of gastrointestinal involvement in systemic sclerosis patients (SSc) patients; GI VAS is also a…

Abstracts tagged "patient outcomes and systemic sclerosis"

Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet

What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?

Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors

Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients

Performance of Patient-Reported Outcomes Measurement Information Systems (PROMIS) Promis-29 and Promis Self-Efficacy in Systemic Sclerosis (SSc)

The UCLA Gastrointestinal Tract Questionnaire (GIT)2.0 and GI Visual Analogue Scale(GI-VAS) Reflect Different Aspects of GI Involvement in Systemic Sclerosis